We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+71.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$766M
AUM Growth
+$254M
Cap. Flow
+$25.8M
Cap. Flow %
3.37%
Top 10 Hldgs %
55.55%
Holding
68
New
13
Increased
17
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.81M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$7.36M
3
FSDC
FS Development Corp. Class A Common Stock
FSDC
+$7.27M
4
CYTK icon
Cytokinetics
CYTK
+$6.84M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$5.6M

Top Sells

Rank Stock Value
1
ATXI
Avenue Therapeutics, Inc. Common Stock
ATXI
+$10.7M
2
APTO
Aptose Biosciences, Inc.
APTO
+$5.22M
3
FULC icon
Fulcrum Therapeutics
FULC
+$4.11M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$3.76M
5
MGNX icon
MacroGenics
MGNX
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.38B
$135M 17.6%
6,510,000
+525,800
+9% +$7.81M
TARA icon
2
Protara Therapeutics
TARA
$236M
$61.9M 8.09%
2,558,472
– –
EIDX
3
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$41.5M 5.42%
315,550
– –
ETON icon
4
Eton Pharmaceutcials
ETON
$1.79B
$32.8M 4.29%
4,040,000
+400,000
+11% +$3.09M
CDXS icon
5
Codexis
CDXS
$182M
$30.6M 3.99%
1,400,000
– –
CRDF icon
6
Cardiff Oncology
CRDF
$76.7M
$29.9M 3.91%
1,662,500
-69,100
-4% -$1.21M
TCON
7
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$29.5M 3.85%
125,919
+25,247
+25% +$3.51M
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
$21.7M 2.83%
350,000
-6,000
-2% -$344K
AFIB
9
DELISTED
Acutus Medical Inc
AFIB
$21.6M 2.82%
749,990
– –
HROW icon
10
Harrow
HROW
$1.44B
$21M 2.75%
3,065,416
+106,416
+4% +$600K
TGTX icon
11
TG Therapeutics
TGTX
$8.53B
$20.2M 2.63%
387,500
-2,500
-0.6% -$84.5K
XOMA
12
DELISTED
Xoma
XOMA
$20.1M 2.62%
455,000
– –
NGNE icon
13
Neurogene
NGNE
$758M
$19.5M 2.55%
69,315
– –
CMRX
14
DELISTED
Chimerix, Inc.
CMRX
$19.1M 2.5%
3,956,500
+115,000
+3% +$417K
CLDX icon
15
Celldex Therapeutics
CLDX
$3.18B
$17.4M 2.27%
992,000
– –
STXS icon
16
Stereotaxis
STXS
$147M
$15.4M 2.01%
3,021,436
– –
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12.7M 1.66%
222,000
– –
FBIO icon
18
Fortress Biotech
FBIO
$93.4M
$12.3M 1.61%
259,167
+3,834
+2% +$166K
CYTK icon
19
Cytokinetics
CYTK
$10.8B
$12.1M 1.58%
582,800
+374,000
+179% +$6.84M
MYOV
20
DELISTED
Myovant Sciences Ltd.
MYOV
$10.5M 1.37%
682,500
– –
LUMO
21
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$10M 1.31%
281,287
+40,395
+17% +$697K
MCRB icon
22
Seres Therapeutics
MCRB
$49.7M
$9.8M 1.28%
16,766
– –
BHVN
23
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.77M 1.28%
114,000
-350
-0.3% -$29.7K
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$8.93M 1.17%
470,203
– –
PCVX icon
25
Vaxcyte
PCVX
$9.1B
$8.91M 1.16%
335,200
+22,200
+7% +$825K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2020 Portfolio in Review

As of Q4 2020, Opaleye Management held 68 positions worth $766M, up 50% from $511M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opaleye Management deployed $25.8M of net new capital in Q4 2020, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aptose Biosciences, Inc., an estimated $5.22M trimmed.

  • Opaleye Management's largest Q4 2020 buy was Tricida, Inc. Common Stock: 959,000 shares worth $6.76M.
  • Opaleye Management added most to Ocular Therapeutix in Q4 2020, an estimated $7.81M increase.
  • Opaleye Management's biggest Q4 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $5.22M.
  • Opaleye Management fully exited Avenue Therapeutics, Inc. Common Stock in Q4 2020, selling an estimated $10.7M.
  • Opaleye Management's ten largest holdings make up 56% of its $766M portfolio in Q4 2020.
  • Opaleye Management opened 13 new positions and closed 9 in Q4 2020.
  • Opaleye Management's portfolio value rose 50% quarter-over-quarter to $766M.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.